Contributed by:

PharmaVOICE Staff

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Let’s talk About Mental Health In Men

Otsuka has launched an original video series entitled “Let’s Talk! We’re Better Together” to encourage conversations about mental wellness. Social stigma is an intimidating reality for many people suffering with mental illness, so the last thing one may think to do is talk about it. Studies show that men represent one of the more reluctant populations to discuss how they feel.

The latest episode of the series features employees who were college athletes, and follows a very candid conversation that follows their transition from student-athlete to 9 to 5 job and adulthood.

U.S. Continues to Lead New Drug R&D

Recent launches of new active substances (NAS) and a strong R&D pipeline indicate that recent global drug development not only has been robust, but also is poised for even stronger growth over the coming decade, according to a study recently completed by the Tufts Center for the Study of Drug Development.

The U.S. share of first launches worldwide remained dominant at 60% to 65% during the 2013 to 2017 timeframe, having increased steadily from a low of 45% in 2010.
China, India, and South Korea, which have focused heavily on vaccine development to date, are becoming ever more important players in global R&D, while the lack of significant development infrastructure, among other factors, has stymied NAS development elsewhere. During the last year, the number of Chinese firms developing NAS jumped 20%, from 219 to 262.

Spending on Medicines Grows

Total spending on medicines is expected to top $1.5 trillion by 2023, up 50% from 2014, even as annual growth moderates at 3% to 6% CAGR compared with 6.3% over the past five years, according to research from the IQVIA Institute for Human Data Science. The study found global drug spending reached $1.2 trillion in 2018, with the key drivers of growth during the next five years to be the United States and pharmerging markets with 4% to 7% and 5% to 8% compound annual growth respectively. Other findings:

The number of new products launched is expected to increase from an annual average of 46 in the past five years to an average of 54 through 2023. The annual average spending in developed markets on new brands is expected to rise slightly to $45.8 billion in the next five years but will represent a smaller share of brand spending.

Use of AI and machine learning by life-sciences companies will accelerate and become the norm. The use of smart algorithms to analyze large complex datasets is most advanced currently in areas of clinical and preclinical research and has applications in assessing preclinical compounds, identifying potential targets based on real-world data, and in driving efficiencies in clinical development.

Mobile apps are increasingly being submitted to the FDA for clearance or approval. These prescription digital therapeutics are a new emerging treatment modality with indications and disease-specific treatment effectiveness claims in their prescribing labels.

Society for Clinical Research Sites Names New President

The Society for Clinical Research Sites (SCRS) has appointed Casey Orvin president. Mr. Orvin brings nearly 20 years of experience within the clinical research industry to SCRS. He most recently worked at Radiant/Synexus, where he was VP of business development.

Mr. Orvin was selected for the role by the company’s late founder and president, Christine Pierre, who passed away from ocular melanoma in October 2018.(PV)



CSL Named One of the Best Employers in the US for Diversity
Forbes magazine has named the global biotechnology company CSL as one of The Best Employers for Diversity in the United States. CSL, the fifth-largest biotechnology company in the world, ranked No. 39 in the business magazine’s annual list of the best 500 employers for diversity. This achievement reflects CSL’s focus to build a workplace culture where employees have a promising future and can fulfill their career aspirations, realize their potential and be part of a purpose-driven company that focuses on saving and protecting the lives of people around the world.

Johnson & Johnson Named a 2019 Fortune World’s Most Admired Company
Johnson & Johnson has been named to Fortune’s list of the World’s Most Admired Companies for the 17th year, ranking in the top 20. Johnson & Johnson also placed No. 1 in the pharmaceutical category worldwide for the sixth consecutive year, making it the highest-ranked healthcare company to appear on the top companies list in 2019.

Lilly Honored for Accelerating Progress for Women in the Workplace
Eli Lilly has received the prestigious 2019 Catalyst Award for its bold and forward-thinking initiatives that help create safe and inclusive workplaces where women can advance. Lilly was honored for its Employee Journeys and People Strategy program. Using storytelling and experience-sharing to address employee-reported biases and barriers, this global initiative focuses on “moments of truth” and creating a common language to help employees understand one another’s experiences.

Parexel Receives Recognitions for its Workplace Culture
Parexel as once again been recognized for its diverse and flexible workplace by Forbes and FlexJobs. For the second consecutive year, the company was named to Forbes’ America’s Best Employers for Diversity, ranking highest among CROs included. The ranking is based on results of independent survey responses from more than 50,000 Americans working for companies from various markets including healthcare, technology and more, and also factors in executive diversity and proactive diversity and inclusion initiatives.

Parexel was also recognized by FlexJobs as a Top 100 Companies with Remote Jobs in 2019, for the sixth consecutive year.

Forbes Recognizes PPD as One of America’s Best Employers for Diversity
Pharmaceutical Product Development (PPD) has been named to Forbes magazine’s 2019 list of America’s Best Employers for Diversity. The recognition follows PPD’s inclusion on Forbes’ 2018 list of America’s Best Large Employers.

Sandoz Certified Global Top Employer 2019
Sandoz, a Novartis division, is honored to announce that it has been officially certified Global Top Employer 2019 for its exceptional employee offerings globally. The certification is based on annual, international research undertaken by the Top Employers Institute that recognizes leading employers around the world and their excellence in employee environment.

Takeda Scoops Prestigious Global Top Employers Award
Takeda Pharmaceutical Company has been named global Top Employer for 2019. Established over 25 years ago, award certification is given annually by the Top Employers Institute to companies with outstanding employee offerings. The program is designed by the Institute to recognize those that create optimal conditions for their employees to develop professionally and personally, and that achieve the highest standards of excellence for their people.


PV100 News

Amicus Therapeutics’ Jayne Gershkowitz Honored by BioNJ
Jayne Gershkowitz, chief patient advocate, Amicus Therapeutics, was honored at this year’s BioNJ Annual Dinner Meeting & Innovation Celebration with its Heart of BioNJ Award in recognition of her dedication and selfless work on behalf of patients.
She is an expert in issues affecting individuals with rare diseases and their families as they relate to orphan drug development, based on more than 18 years of strategic marketing, resource development, and executive management in the nonprofit healthcare and rare disease patient community organization sector.

Ms. Gershkowitz is a PharmaVOICE 100 — 2018.

W2O’s Jim Weiss Appointed to HBA Advisory Board
Jim Weiss, founder and CEO of W2O, a network of innovative analytics-
driven, digital-first marketing and communications firms, has joined the Healthcare Businesswomen’s Association (HBA) Advisory Board for the 2019-2021 term.

The HBA Advisory Board is comprised of an invited group of senior executives in the healthcare industry who represent a diverse membership. HBA Advisory Board members, who serve a three-year term, provide strategic direction on how the organization can further the advancement of women’s careers in healthcare worldwide through HBA initiatives.

Mr. Weiss is a PharmaVOICE 100 — 2018.

Premier Research Names Dr. Mike Wilkinson Chief Operating Officer
Premier Research has named CRO industry and military veteran Dr. Mike Wilkinson as its new chief operating officer. He brings a diverse background of industry and public service to his role of overseeing the company’s day-to-day operations and advancing its mission to support the world’s leading biotech innovators. Dr. Wilkinson spent 10 years at PPD, most recently as PPD’s chief information officer and head of technology, responsible for data, process improvement, and global training.
Dr. Wilkinson is a PharmaVOICE 100 — 2016.


PharmaVOICE @Industry Events

2019 BioNJ Celebration

The 2019 BioNJ Annual Dinner Meeting & Innovation Celebration drew more than 700 biotechnology and pharmaceutical professionals, government officials, academic leaders and professional service providers. New Jersey Governor Phil Murphy provided the opening address, emphasizing the considerable role that the state plays in the healthcare ecosystem — 21 of 50 new novel drug approvals in 2018 came from a company with a footprint in New Jersey.

Advanced Accelerator Applications (a Novartis Co.) for Lutathera
Allergan for Seysara
Amicus Therapeutics for Galafold
Eli Lilly and Company for Olumiant and Emgality
GlaxoSmithKline for Krintafel
Helsinn for Akynzeo
Insmed for Arikayce
Janssen Biotech for Erleada
Kyowa Kirin Pharmaceutical Development for Poteligeo
Merck & Co. for Pifeltro
Otsuka America Pharmaceutical for Jynarque
Pfizer for Daurismo, Lorbrena, Talzenna Vizimpro
Regeneron Pharmaceuticals for Libtayo
Sanofi for Libtayo
Shionogi for Mulpleta and Xofluza
Sun Pharmaceutical Industries for Ilumya
Teva Pharmaceutical Industries for Ajovy

The Dr. Sol J. Barer Award was presented to Global Head of Johnson & Johnson, External Innovation Dr. William N. Hait by Dr. Sol J. Barer. The Heart of BioNJ Award was presented to Jayne Gershkowitz, chief patient advocate, Amicus Therapeutics and 10-year old patient advocate Max Schill, who personally walked the halls of Congress to advocate for the 21st Century Cures Act.



Contributed Articles
Social Listening Identifies Unmet Needs of Rare Disease Patients: An Inspire Case Study
Provided by: Inspire

Physicians Demand RWE To Move Prescriptions, Reveals Survey
Provided by: PharmaFuture

OnDemand: Designing and Measuring Engagement in Behavior Change Interventions
Sponsored by: Mad*Pow

Successfully Managing & Implementing Orphan Drug Development Program
Provided by: UBC

White Papers
Achieving launch excellence in the challenging health markets of today
Provided by: Blue Latitude Health

Detecting Pharmacy Fraud: Is Your Brand’s Co-Pay Program Protected?
Provided by: TrialCard

Invert to Convert: Rethinking Patient Recruitment and Enrollment Strategies
Provided by: WIRB Copernicus Group


Posted in:

Post a Comment

You must be logged in to post a Comment.